12:00 AM
Apr 08, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Benlysta belimumab: Phase III started

GlaxoSmithKline began a double-blind, placebo-controlled Phase III trial to evaluate 10 mg/kg IV Benlysta plus 2 mg/kg oral azathioprine daily in about 400 patients with Wegener's granulomatosis or microscopic polyangiitis. Patients will...

Read the full 150 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >